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Abstract
Introduction: Alzheimer’s disease (AD) is widely recognized as a serious public health problem and heavy financial
burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently, we
demonstrated that stem cell factor (SCF) in combination with granulocyte colony-stimulating factor (G-CSF) (SCF
+G-CSF) has therapeutic effects on chronic stroke. The purpose of the present study is to determine whether SCF
+G-CSF can reduce the burden of b-amyloid deposits in a mouse model of AD.
Methods: APP/PS1 transgenic mice were used as the model of AD. To track bone marrow-derived cells in the
brain, the bone marrow of the APP/PS1 mice was replaced with the bone marrow from mice expressing green
fluorescent protein (GFP). Six weeks after bone marrow transplantation, mice were randomly divided into a saline
control group and a SCF+G-CSF-treated group. SCF in combination with G-CSF was administered subcutaneously
for 12 days. Circulating bone marrow stem cells (CD117
+ cells) were quantified 1 day after the final injection. Nine
months after treatment, at the age of 18 months, mice were sacrificed. Brain sections were processed for
immunohistochemistry to identify b-amyloid deposits and GFP expressing bone marrow-derived microglia in the
brain.
Results: Systemic administration of SCF+G-CSF to APP/PS1 transgenic mice leads to long-term reduction of
b-amyloid deposition in the brain. In addition, we have also observed that the SCF+G-CSF treatment increases
circulating bone marrow stem cells and augments bone marrow-derived microglial cells in the brains of APP/PS1
mice. Moreover, SCF+G-CSF treatment results in enhancement of the co-localization of bone marrow-derived
microglia and b-amyloid deposits in the brain.
Conclusions: These data suggest that bone marrow-derived microglia play a role in SCF+G-CSF-induced long-term
effects to reduce b-amyloid deposits. This study provides insights into the contribution of the hematopoeitic
growth factors, SCF and G-CSF, to limit b-amyloid accumulation in AD and may offer a new therapeutic approach
for AD.
Introduction
Alzheimer’s disease (AD) is the major cause of dementia
and the sixth leading cause of death in the United States
[1]. Currently, no treatment has been proven to stop
AD. Although the cause of AD remains uncertain, sub-
stantial evidence shows that toxic b-amyloid peptide
plays a critical role in the progress of this devastating
disease [2].
The microglial cells that cluster around b-amyloid pla-
ques had been thought to participate in the pathogenesis
of AD. Microglia activated by b- a m y l o i dm a yb ea s s o -
ciated with detrimental inflammation in the brain of AD
[3]. Recent studies, however, have demonstrated that
microglia also have beneficial effects in AD [4,5]. Inter-
estingly, bone marrow-derived microglia appear to be
efficient in clearance of b-amyloid deposits [6].
Stem cell factor (SCF) and granulocyte colony-stimu-
lating factor (G-CSF) are the hematopoeitic growth fac-
tors that are critically involved in regulation of blood
cell production and mobilization of bone marrow stem
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that SCF [9] and G-CSF [9-11] alone or in combination
(SCF+G-CSF) [9] have therapeutic effects in animal
models of acute [9-11] or chronic stroke [12]. Moreover,
our previous study has shown that SCF+G-CSF has
stable and long-term effects to improve somato-sensori-
motor function in chronic stroke as compared with SCF
or G-CSF alone [12]. Further, in a short-term study,
G-CSF has been shown to decrease b-amyloid deposi-
tion and to increase total load of microglia in a mouse
model of AD [13].
T h ep u r p o s eo ft h ep r e s e n ts t u d yi st od e t e r m i n e
whether SCF+G-CSF has a long-term effect to reduce
the burden of b-amyloid deposits in a mouse model
of AD.
Materials and methods
All procedures were approved by the Institutional Ani-
mal Care and Use Committee of Louisiana State Univer-
sity Health Sciences Center and are in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Animal model of Alzheimer’s disease
The mouse model of AD used for the present study is
an amyloid precursor protein/presenilin 1 (APP/PS1)
transgenic strain. This transgenic strain of AD was ori-
ginally developed by Jankowsky and coworkers, who
inserted two human mutant genes of AD, APP and PS1
into a single locus [14]. The genetic background of
APP/PS1 mice used for the present study is C57BL/6J.
T h e s et r a n s g e n i cm i c eh a v eb e e ns h o w nt od e v e l o p
b-amyloid deposits in the cortex and hippocampus
by 6 to 7 months of age [15] (Jackson Laboratory,
Bar Harbor, ME, USA). In this study, male APP/PS1
mice were used.
Experimental design
To track bone marrow-derived cells in the brain,
7-month-old APP/PS1 mice received X-ray irradiation
to destroy their bone marrow, and the bone marrow of
the mice expressing green fluorescent protein (GFP)
(UBC-GFP mice with the genetic background of C57BL/
6J, as with APP/PS1 mice) was transplanted to the APP/
PS1 mice. Six weeks after bone marrow transplantation,
mice were randomly divided into a saline control group
(n = 5) and an SCF+G-CSF-treated group (n =5 ) .S C F
+G-CSF or an equal volume of saline was injected sub-
cutaneously for 12 days. One day after the final injec-
tion, the number of CD117-positive hematopoietic stem
cells in peripheral blood was determined using flow
cytometry. Nine months after treatment, at the age of
18 months, the mice were sacrificed and brain sections
were processed for immunohistochemistry (Figure 1a).
Bone marrow transplantation and hematopoietic growth
factor administration
To destroy the bone marrow, APP/PS1 mice were exposed
to a lethal dose of X-ray irradiation (900 rad). The ends of
each femur from UBC-GFP mice (8 to 10 weeks old)
(Jackson Laboratory) were clipped to expose the marrow.
The bone marrow was flushed out by 10 ml ice-cold
Hanks Balanced Salt Solution in a syringe with a 21-gauge
needle, followed by filtration through a 70-mm nylon
mesh to obtain a single cell suspension. The bone marrow
cells were centrifuged, resuspended with Hanks Balanced
Salt Solution, and transplanted to the APP/PS1 mice
through the tail vein. Bone marrow transplantation (10
7
cells per mouse) was performed within 24 hours after irra-
diation. Mouse recombinant SCF (100 μg/kg) (PeproTech,
Rocky Hill, NJ, USA) with human recombinant G-CSF
(50 μg/kg) (Amgen, Thousand Oaks, CA, USA) or
an equal volume of saline was administered subcuta-
neously for 12 days, beginning 7 weeks after bone marrow
transplantation.
Flow cytometry
Blood was collected from the tails of mice. Red blood
cells were then lysed with a fluorescence-activated cell-
sorting lysis buffer (BD Pharmingen, Franklin Lakes, NJ,
USA) and washed with PBS containing 0.5% fetal bovine
serum. The remaining cells were resuspended in PBS
containing 0.5% fetal bovine serum and labeled with
APC-conjugate anti-mouse CD117 antibody (anti-ckit,
1:100) or an equal amount of isotype-matched APC
antibodies (eBioscience, San Diego, CA, USA) on ice for
30 minutes. The total of 5 × 10
6 cells was then analyzed
by flow cytometry (FACSCalibur, BD, Franklin Lakes,
NJ, USA).
Immunohistochemistry
A tt h ee n do ft h ee x p e r i m e n t ,A P P / P S 1m i c ew e r e
transcardially perfused with PBS followed by 4% buf-
fered formaldehyde. The brains were removed and
placed in 4% buffered formaldehyde overnight at 4°C,
and the brains were then cryoprotected by overnight
immersion in 30% sucrose. Coronal brain sections,
30 μm thick, were cut with a microtome (Leica SM
2000R; Leica Microsystems Nussloch GmbH, Nussloch,
Germany). The free-floating method was used for
immunohistochemistry. Briefly, nonspecific binding was
blocked by 5% normal goat serum diluted in 1% bovine
serum albumin (IgG-free) (Jackson ImmunoResearch
Labs, West Grove, PA, USA) with 0.25% Triton X-100.
Brain sections were then incubated with primary antibo-
dies, rabbit or mouse anti-GFP (1:200) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), mouse anti-b-
amyloid (1:1,000) (clone 4G8; Signet Laboratories,
Dedham, MA, USA), or rabbit anti-Iba 1 (1:500) (Wako,
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sections were incubated with Cy2-conjugated, Cy3-con-
jugated or Cy5-conjugated goat anti-mouse or anti-rab-
bit antibodies (Jackson ImmunoResearch) for 2 hours at
room temperature in the dark. Sections were counter-
stained with 4’,6-diamidino-2-phenylindole (50 ng/ml)
(Sigma, St Louis, MO, USA) and mounted with ProLong
Gold anti-fade reagent (Invitrogen, Grand Island, NY,
USA). Brain sections without the primary antibodies
served as negative controls. Four sections per each brain
were processed for immunohistochemistry.
Immunofluorescent image analysis
Images of immunofluorescent staining in brain sections
were captured with a Zeiss confocal microscope
(LSM510 NLO; Zeiss, Thornwood, NY, USA). Z-stacks,
16 serial optical sections with 2 μmi n t e r v a l s ,w e r e
acquired from the cortex and hippocampus to detect
the co-expression of GFP, Iba-1
+ cells, and nuclear dye
(4’,6-diamidino-2-phenylindole). Images taken from
eight selected areas in the cortex and from nine selected
areas in the hippocampus of each brain section (indi-
cated in Figure 1b, c) were used for quantifying b-
amyloid plaques and GFP
+/Iba-1
+ cells. NIH Image J
software was used for the quantitative analysis [16]. The
b-amyloid load was calculated as the percentage of
selected area that was occupied by the b-amyloid immu-
nofluoresent staining. The process of cell counting was
performed in a blinded manner.
Statistical analysis
Statistical significances of changes in circulating bone
marrow stem cells, bone marrow-derived cells, bone
marrow-derived microglial cells and the b-amyloid
deposits in the brain were assessed with Student’s t test.
The chi-square test was used for analyzing the ratio of
bone marrow-derived cells appearing in b-amyloid pla-
ques. P < 0.05 was considered significant, and data are
expressed as the mean ± standard error.
Results
Stem cell factor plus granulocyte colony-stimulating
factor treatment mobilized bone marrow stem cells into
the blood in APP/PS1 transgenic mice
To determine whether the treatment of SCF+G-CSF
mobilizes bone marrow stem cells in APP/PS1 mice,
peripheral blood was collected 1 day after the final
injection of SCF+G-CSF, and the levels of circulating
bone marrow stem cells expressing CD117 (c-kit) were
examined using flow cytometry. We found that the per-
centage of CD117 expressing cells was significantly
increased more than seven times in SCF+G-CSF-treated
mice (saline control: 1.99 ± 0.98%, SCF+G-CSF: 15.35 ±
3.0%) (P < 0.01), indicating that the treatment paradigm
is sufficient to mobilize bone marrow stem cells into the
blood in the APP/PS1 transgenic mice.
Stem cell factor plus granulocyte colony-stimulating
factor treatment decreased b-amyloid deposition in APP/
PS1 transgenic mice
Next we sought to determine whether SCF+G-CSF
treatment induced a long-term reduction in the burden
of b-amyloid deposits. The 12-day treatment of SCF+G-
CSF started at the age of 9 months, at which the time
point b-amyloid deposition in the brains of APP/PS1
mice had already occurred. The APP/PS1 mice were
sacrified 9 months after the treatment, at the age of
18 months. b-amyloid deposits both in the cortex and
hippocampus were examined by immunohistochemistry.
We observed that b-amyloid deposits were abundant
Figure 1 Experimental design and image collection in the brain sections of this study. (a) Schematic chart of the experimental design.
Selected areas for acquiring confocal images in (b) the cortex and (c) the hippocampus. BM, bone marrow; G-CSF, granulocyte colony-
stimulating factor; i.v., intravenous; s.c., subcutaneously; SCF, stem cell factor.
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(1.08 ± 0.12%) of control APP/PS1 mice; however, SCF
+G-CSF treatment significantly reduced the load of
b-amyloid deposits in these regions (cortex: 1.11 ±
0.27%; hippocampus: 0.62 ± 0.15%) (P < 0.05 compared
with the controls) (Figure 2). These data suggest that
SCF+G-CSF treatment induces a long-term reduction of
b-amyloid load and that the treatment may contribute
to removal of b-amyloid deposits in the brain.
Stem cell factor plus granulocyte colony-stimulating
factor treatment enhanced co-localization of bone
marrow-derived microglial cells and b-amyloid plaques in
APP/PS1 transgenic mice
We then asked what types of cells were involved in the
clearance of b-amyloid deposits in the brains of APP/
PS1 mice. The brain samples were collected 9 months
after treatment. When quantifying the bone marrow-
derived cells (GFP
+ cells) in the brain, we found there
Figure 2 b-amyloid deposits in the brains of APP/PS1 mice. (a), (b) High-power images of b-amyloid (Ab) deposits in the cortex. b-amyloid
deposits are identified with anti-b-amyloid antibody (clone 4G8) (red). (c), (d) Low-power images of b-amyloid deposits in the cortex. Red dots
are b-amyloid deposits. (e) Quantification of b-amyloid deposits in the cortex. (f), (g) High-power images of b-amyloid deposits (red) in the
hippocampus. (h), (i) Low-power images of b-amyloid deposits (red) in the hippocampus. (j) Quantification of b-amyloid deposits in the
hippocampus. Note that b-amyloid burdens both in the cortex and hippocampus are significantly decreased by stem cell factor and granulocyte
colony-stimulating factor (SCF+G-CSF). Cell nuclei are stained with 4’,6-diamidino-2-phenylindole (DAPI) (blue). Data presented as mean ±
standard error. *P < 0.05. Scale bar: (b) 100 μm (for images in (a), (b), (f) and (g)); (d), (i) 200 μm (for images in (c), (d), (h) and (i)).
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+ cells
(control vs. SCF+G-CSF: 100 ± 23.3 vs. 154.7 ± 48.9).
Next we used Iba1 antibody to identify microglial cells,
as Iba1 has been characterized as a specific marker
for macrophage/microglia [17]. We observed that the
number of GFP
+/Iba1
+cells in the brains of SCF+G-
CSF-treated mice was twofold higher than the controls
(control vs. SCF+G-CSF: 100 ± 48.6 vs. 206.4 ± 77.5).
The resident Iba1
+cells in the brain, however, did not
show significant difference between these two groups
(control vs. SCF+G-CSF: 100 ± 7.3 vs. 106.5 ± 8.0).
These data suggest that SCF+G-CSF treatment induces
a long-term effect on homing of bone marrow-derived
cells into the brains of APP/PS1 mice, and that this
treatment causes selective accumulation of bone
marrow-derived Iba1
+ microglial cells in the brains of
APP/PS1 mice.
Bone marrow-derived microglial cells have been
shown to participate in removal of b-amyloid deposits
in the brain [6]. We therefore sought to determine the
co-localization of bone marrow-derived microglial cells
and b-amyloid plaques. We performed triple immuno-
fluorescent labeling of GFP, Iba1 and b-amyloid plau-
ques, and found that the co-localization of b-amyloid
plaques and GFP
+/Iba1
+cells in brains of SCF+G-CSF-
treated mice (15.5 ± 6.7%) was significantly higher than
in control group (5.5 ± 2.2%) (Figure 3). In other studies
we have observed that the number of GFP
+ cells and
GFP
+/Iba1
+cells, and the co-localization of GFP
+/Iba1
+cells and b-amyloid plaques in the brains of APP/PS1
mice are significantly increased by SCF+G-CSF immedi-
ately after a 12-day treatment (Li B, Liu XY, Zhao LR,
unpublished obervations). These findings suggest that
SCF+G-CSF treatment may enhance the effect of bone
marrow-derived microglial cells on clearance of b-amy-
loid plaques.
Discussion
The main findings of the present study are that systemic
administration of SCF+G-CSF in APP/PS1 transgenic
mice leads to long-lasting effects to reduce the b-amy-
loid burden. In addition, we have also revealed that the
treatment enhances the co-localization of bone marrow-
derived microglia and b-amyloid deposits in the brains
of APP/PS1 mice.
In agreement with our present findings, G-CSF treat-
ment in mouse models of AD has been shown to reduce
the b-amyloid burden in a short-term study. Using APP/
PS1 mice, Sanchez-Romos and coworkers observed that
subcutaneous injection of G-CSF every other day for
3 weeks lead to acute b-amyloid reduction when exam-
ined in the third week of G-CSF injection [13]. In addi-
tion to the acute benefits, the present study shows
that SCF+G-CSF treatment in APP/PS1 mice induces
long-lasting effects to reduce b-amyloid load in the
brain, suggesting a significant and crucial role of the
combination treatment with SCF and G-CSF in AD. At
present, however, how and why SCF+G-CSF treatment
causes such long-term benefits in AD remains unclear.
Clearly, this uncertainty will lead to many future studies
to address these questions.
Mobilization of bone marrow stem cells and homing
of bone marrow-derived cells in the brain are enhanced
by SCF+G-CSF in AD mice. CD117, also called c-kit, is
expressed on the surface of hematopoietic stem cells
[18]. About 1 to 3% of peripheral blood mononuclear
cells express CD117 antigen [19]. In this study, we
observed that systemic administration of SCF+G-CSF in
APP/PS1 mice significantly elevated CD117
+ cells in
peripheral blood, indicating that the treatment paradigm
is sufficient to mobilize bone marrow-derived stem cells.
This finding is in line with other studies, which have
shown that SCF in combination with G-CSF signifi-
cantly increases the number of bone marrow stem cells
in the peripheral blood [20-22]. It has been shown that
bone marrow-derived cells can pass through the blood-
brain barrier in adult brain [23]. In addition to mobiliza-
tion of bone marrow-derived cells into the blood, SCF
+G-CSF treatment has also been found to enhance the
recruitment of bone marrow-derived cells into the adult
brain [22,24]. Here we have shown that bone marrow-
derived cells tended to a significant increase (1.5-fold
increase) in the brains of APP/PS1 mice for a long per-
iod (9 months) after SCF+G-CSF treatment. In an acute
study, however, we observed a significant increase in
bone marrow-derived cells immediately after a 12-day
subcutaneous injection of SCF+G-CSF in APP/PS1 mice
(Li B, Liu XY, Zhao LR, unpublished observations), sug-
gesting the ability of homing bone marrow-derived cells
into the brains of APP/PS1 mice by SCF+G-CSF
treatment.
The fate of bone marrow-derived cells in the brain is
dependent upon the microenvironment of the brain. In
our previous study, we revealed that SCF+G-CSF treat-
ment augmented bone marrow-derived endothelial cells
and neurons in the cortex of the chronic stroke brain.
The number of bone marrow-derived microglia in the
brain in chronic stroke, however, was not different
between SCF+G-CSF-treated and mock-treated controls
[22]. In the present study, we found a twofold increase
in bone marrow-derived microglial cells (GFP
+/Iba1
+)i n
the brains of APP/PS1 mice 9 months after SCF+G-CSF
treatment. In our acute study, a significant increase
(fivefold) in the number of bone marrow-derived micro-
glial cells in the brain was seen in SCF+G-CSF-treated
APP/PS1 mice on the last day of a 12-day injection of
SCF+G-CSF (Li B, Liu XY, Zhao LR, unpublished obser-
vations), suggesting that SCF+G-CSF treatment leads to
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marrow-derived cells in brain with b-amyloid deposits.
Other studies also provide supportive evidence that the
microenvironment of the brain with b-amyloid deposits
facilitates the microglial lineage determination of bone
marrow-derived cells, so that injection of b-amyloid
peptides into the brain is reported to cause an increase
in the number of bone marrow-derived microglia [6].
Interestingly, G-CSF treatment elevated the microglial
burden in APP/PS1 transgenic mice, but this treatment
has no effect in wild-type mice [13].
Bone marrow-derived microglial cells participate in clear-
ance of b-amyloid deposits. Microglia are the macrophages
carrying out tissue maintenance and immune surveillance
in the brain. During development, the microglial progeni-
tors, derived from mesenchymal myeloid linage progenitor
cells, migrate into the embryonic brain before maturation
of the blood-brain barrier [25]. In the normal mature
brain, the resident microglial cells are renewed by prolifera-
tion of endogenous microglia, whereas infiltration of per-
ipheral monocytes into the brain is rare except in brain
lesions [26]. Deposition of senile plaques is one of the
pathological hallmarks of AD, and aggregated b-amyloid
peptides are the major components of senile plaques.
b-amyloid aggregates are clearly known to induce synaptic
dysfunction and neuronal dystrophy [2].
A variety of studies have demostrated increased num-
bers of active microglia in the brains of AD patients and
Figure 3 Association between bone marrow-derived microglia and b-amyloid plaques in the brains of APP/PS1 mice. (a), (b)
Immunohistochemical identification of bone marrow-derived microglia and b-amyloid (Ab) plaques. Bone marrow-derived cells are the cells
expressing green fluorescent protein (GFP) (green). Microglia are identified with an anti-Iba1 antibody (red). Yellow cells are the bone marrow-
derived microglia that are co-labeled with GFP and Iba1. b-amyloid deposition is determined with an anti-b-amyloid antibody (clone 4G8) (blue).
The white arrows indicate b-amyloid deposits surrounded by bone marrow-derived microglial cells (yellow). (c) High-magnification confocal
images of the image indicated with dashed lines in (b). (d) Quantification of the bone marrow-derived microglia associated with b-amyloid
plaques in the brain. Data presented as mean ± standard error. *P < 0.05. Scale bar: (b) 100 μm (for both images in (a) and (b)); (c) 25 μm. G-
CSF, granulocyte colony-stimulating factor; SCF, stem cell factor.
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b-amyloid aggregates [27]. A recent study showed that,
following injection of fibrillar b-amyloid into the brain
cortex of aged monkeys, active migroglia mediated fibril-
lar b-amyloid-induced neuron loss [28]. Although it is
not clear whether the neurotoxic effects are mediated by
resident microglial cells or by bone marrow-derived
microglia, Leung and colleagues isolated microglia from
the brains of aged monkeys and revealed that fibrillar
b-amyloid increased in the production of reactive oxy-
gen species, which are toxic to neurons, in microglia
[28]. In our study, we did not observe an increase in
resident microglial cells in the brains of SCF+G-CSF-
treated APP/PS1 mice. However, bone marrow-derived
microglia in the brain were increased by the treatment.
Why the treatment selectively increases the number of
bone marrow-derived microglia, and whether the bone
marrow-derived microglia are more beneficial than the
resident microglia in the brain with b-amyloid deposits
are interesting questions that should be addressed in
future studies.
Accumulating evidence has recently suggested that the
peripheral monocytes penetrating into the brain in AD
m a yp l a yar o l ei nc l e a r a n c eo fb-amyloid. A signifi-
cantly higher number of bone marrow-derived microglia
colocalizes with b-amyloid plaques, and the bone mar-
row-derived microglial cells effectively phagocytose and
remove b-amyloid deposits from the brains of APP/PS1
mice [6]. In the present study, we found a significant
reduction in b-amyloid load in the brain 9 months after
SCF+G-CSF treatment. In addition, at this time point a
significant increase (2.8-fold) in the co-localization of
bone marrow-derived microglial cells and b-amyloid
deposits was seen in the brains of SCF+G-CSF-treated
APP/PS1 mice. As mentioned earlier, in our acute study,
SCF+G-CSF treatment resulted in a significant increase
(> 11-fold) in the co-localization of bone marrow-
derived microglial cells and b-amyloid deposits (Li B,
Liu XY, Zhao LR, unpublished observations). These data
s u g g e s tt h a tt h eS C F + G - C S F - i n d u c e dl o n g - t e r mr e d u c -
tion in b-amyloid burden may be associated with a
long-lasting enhancement in clearance of b-amyloid
deposits by bone marrrow-derived microglial cells. How
SCF+G-CSF enhances the clearance function of bone
marrrow-derived microglia to remove b-amyloid, how-
ever, remains to be determined in future studies.
Both SCF and G-CSF have recently been demon-
strated to be decreased in the plasma of patients with
early AD [29,30]. In the present study, we have demon-
strated, for the first time, a significant contribution of
systemic administration of SCF and G-CSF to long-term
reduction in b-amyloid burden in the brain. A combina-
tion of these two hematopoeitic growth factors, SCF and
G - C S F ,m a yt h u sp r o v i d ean e wt h e r a p e u t i ca p p r o a c h
for the treatment of AD.
Conclusions
In summary, the present study provides evidence that
SCF+G-CSF treatment results in a long-term decrease
in b-amyloid load in APP/PS1 transgenic mice. This
therapeutic affect may be associated with SCF+G-CSF-
induced increase in clearance of b-amyloid deposits
through the enhancement of bone marrow-derived
microglial cells. These data suggest that treatment with
the hematopoeitic growth factors SCF and G-CSF may
open an new avenue to develop therapeutic strategies
for improving the health of individuals who suffer
from AD.
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